Justin Smith's questions to AstraZeneca PLC (AZN) leadership • Q1 2025
Question
Justin Smith requested more color on the increased competition for Ultomiris, asking if it was price-related and how it aligns with competitors' views that innovation should expand the market.
Answer
EVP, Rare Disease, Marc Dunoyer clarified that the competition for Ultomiris comes primarily from novel medicines with different mechanisms of action, not biosimilars or price pressure. He agreed that innovation is expanding the myasthenia gravis market, where Ultomiris holds a key position, but other novel therapies are also attracting patients new to branded treatments.